Ara
Toplam kayıt 42, listelenen: 21-30
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
(Wolters Kluwer Medknow Publications, 2023)
Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective
treatment for NASH. This randomized, multicenter, double-blind, phase 2b
study ...
The heated debate over NAFLD renaming: An ongoing saga
(Kare Publishing, 2023)
In 1980, Jurgen Ludwig, a pathologist at the Mayo Clinic, and colleagues formally described a disorder that involved the accumulation
of fat in the liver, independent of significant alcohol consumption, or
other secondary ...
Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease
(Elsevier, 2023)
he study by Pischke et al. [1], which explores the relationships
between non-alcoholic steatohepatitis (NASH) and periodontitis, warrants commendation. The analysis involved 32 patients with NASH and
100 randomly, ...
TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease
(Kare Publishing, 2023)
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become ...
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
(SpringerNature, 2023)
Recompensation has gained increasing attention in the feld of cirrhosis,
particularly in chronic liver disease with a defnite aetiology. The current
global prevalence of obesity and nonalcoholic fatty liver disease
(NAFLD) ...
Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis
(Kare Publishing, 2023)
Background and Aim: Our primary objective is to examine the variance
in chronotype, night-eating patterns, and sleep quality in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. In ...
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
(Elsevier, 2023)
Background
The aim of this study was to evaluate the diagnostic accuracy of simple non-invasive tests (NITs) in NAFLD patients with type 2 diabetes(T2D).
Methods
This was an individual patient data meta-analysis of ...
A multi-society Delphi consensus statement on new fatty liver disease nomenclatureA multisociety Delphi consensus statement on new fatty liver disease nomenclature
(Elsevier, 2023)
The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. ...
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
(Elsevier, 2023)
Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this crosssectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease ...